NUCB2 inhibition antagonizes osteosarcoma progression and promotes anti-tumor immunity through inactivating NUCKS1/CXCL8 axis.
Ji R, Wang Y, Pan D, Han J, Wang Y, Zheng S, Zhao W, Li X, Han C, Zhang L. Cancer Lett. 2024 Jun 1; 591:216893. Epub 2024 Apr 16.